Necitumumab  (Synonyms: 11F8; IMC-11F8; LY3012211)

Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

ERBB1/EGFR/HER1

Necitumumab specifically binds to the EGF binding site of human EGFR with high affinity (dissociation constant 0.32 nM) and blocks ligand binding with an IC₅₀ of 1-2 nM^[1].
Necitumumab neutralizes ligand-induced EGFR phosphorylation with an IC₅₀ of 1.5-3 nM^[1].
Necitumumab inhibits the proliferation of EGFR-dependent colorectal tumour cells with an IC₅₀ of 0.8-1.0 nM^[1].
Necitumumab induces EGFR internalization and degradation, and triggers antibody-dependent cellular cytotoxicity in EGFR-expressing human cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Necitumumab (60 mg/kg; i.p.; twice a week for 2 weeks) yields substantially increased anti-tumour activity in murine non-small-cell lung cancer xenograft models when added to Gemcitabine (HY-17026) and Cisplatin (HY-17394)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1956  [NCBI]

P00533

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.78 kDa

906805-06-9

Liquid

Colorless to light yellow

[Necitumumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human ERBB1/EGFR/HER1, His Tag can bind Necitumumab. The EC₅₀ for this effect is 11.47 ng/mL.
• 
  Flow Cytometry analysis of A431 cells labelling ERBB1/EGFR/HER1 (red) with Necitumumab (anti-ERBB1/EGFR/HER1) (HY-P9964). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. Garnock-Jones KP, et al. Necitumumab: First Global Approval. Drugs. 2016;76(2):283-289.  [Content Brief]

  [2]. Samakoglu S, et al. Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC. Cancer Genomics Proteomics. 2012 Mar-Apr;9(2):77-92.  [Content Brief]